BioSpace News Archive

Atreca, Inc. (Atreca) (NASDAQ: BCEL), today announced the appointment of Dr. Stacey Ma, Executive Vice President and Head of Technical Operations at Sana Biotechnology, and Stephen R. Brady, Chief Executive Officer of Tempest Therapeutics, to its Board of Directors.

Calyxt, Inc. (NASDAQ: CLXT) will hold a conference call on Thursday, August 5, 2021 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended on June 30, 2021.

CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Chief Operating Officer and Head of Clinical Development, will host an investment community webcast on Thursday, July 22, 2021.

Sight Sciences, Inc. today announced the closing of its initial public offering of 11,500,000 shares of common stock including the exercise in full of the underwriters’ option to purchase 1,500,000 additional shares of common stock, at the initial public offering price of $24.00 per share.

Brickell Biotech, Inc. today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,064,517 shares of common stock of the Company at a price to the public of $0.62 per share.

HCW Biologics Inc. today announced the pricing of an underwritten initial public offering of 7,000,000 shares of common stock at a public offering price of $8.00 per share.

Junshi Biosciences announced that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.

Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of preclinical data in nonhuman primates (NHPs) of the company’s intranasal recombinant live attenuated COVID-19 vaccine (MV-014-212).

The allergy immunotherapies market was valued at US$ 1,819.18 million in 2019 and is projected to reach US$ 4,185.89 million by 2027; it is expected to grow at a CAGR of 11.1% from 2020 to 2027.

The bioresorbable medical material market is expected to reach US$ 1,942.13 Mn in 2027 from US$ 935.99 Mn in 2019. The market is estimated to grow with a CAGR of 9.7% from 2020-2027.